Body composition in HIV-infected patients receiving highly active antiretroviral therapy

References

• Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4(3):293–301.10.1046/j.1468-1293.2003.00159.x
   PubMedGoogle Scholar
• Delpierre C, Bonnet E, Marion-Latard F, Aquilina C, Obadia M, Marchou B, et al. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. J Clin Densitom. 2007;10(4):376–380.10.1016/j.jocd.2007.07.006
   PubMed Web of Science ®Google Scholar
• Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis. 2012;205(suppl 3):S383–S390.10.1093/infdis/jis205
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174.10.1097/QAD.0b013e32801022eb
   PubMed Web of Science ®Google Scholar
• Kosmiski L, Kuritzkes D, Hamilton J, Sharp T, Lichtenstien K, Hill J, et al. Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome. HIV Med. 2003;4(3):235–240.10.1046/j.1468-1293.2003.00151.x
   PubMedGoogle Scholar
• Harris VW, Brown TT. Osteopenia, osteoporosis, and fractures in HIV-infected patients: extent of the problem. Clinic Rev Bone Miner Metab. 2012;10(4):246–256.10.1007/s12018-012-9132-z
   Google Scholar
• Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60:1242–1251.10.1093/cid/civ010
   PubMed Web of Science ®Google Scholar
• Chiţu-Tișu CE, Barbu EC, Lazăr M, Ionescu R, Bojinca M, Ion DA, et al. An overview of bone disease in HIV-infected patients. Acta Medica Mediterr. 2015;31:1139–1151.
   Web of Science ®Google Scholar
• World Health Organization. Obesity: preventing and managing the global epidemic. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2014;25(10):2359–2381.10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• World Health Organization. Scientific Group on the assessment of osteoporosis at primary health care level. Summary Meeting Report. Brussels; 2004.
   Google Scholar
• European AIDS Clinical Society (EACS) Guidelines. Version 8. 2015 October. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html Accessed 10/06/2016.
   Google Scholar
• Bergersen BM, Sandvik L, Bruun JN. Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis. 2004;36(3):186–191.10.1080/00365540410019273
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15(11):1389–1398.10.1097/00002030-200107270-00008
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005;40(12):1837–1845.10.1086/430379
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51–F58.10.1097/00002030-199807000-00003
   PubMed Web of Science ®Google Scholar
• Kim RJ, Wilson CG, Wabitsch M, Lazar MA, Steppan CM. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity. 2006;14(6):994–1002.10.1038/oby.2006.114
   PubMed Web of Science ®Google Scholar
• Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab. 1999;84(11):4274–4277.10.1210/jcem.84.11.6234
   PubMed Web of Science ®Google Scholar
• Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63–F67.10.1097/00002030-200003100-00005
   PubMed Web of Science ®Google Scholar
• Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem. 2002;277(22):19247–19250.10.1074/jbc.C200069200
   PubMed Web of Science ®Google Scholar
• Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med. 2006;7(1):38–45.10.1111/hiv.2006.7.issue-1
   PubMed Web of Science ®Google Scholar
• Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther. 2004 Apr;9(2):161–177.
   PubMed Web of Science ®Google Scholar
• Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gibert CL, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr. 2007;44(5):506–517.10.1097/QAI.0b013e31804216cf
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15(6):703–709.10.1097/00002030-200104130-00005
   PubMed Web of Science ®Google Scholar
• Powderly WG. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep. 2012;9(3):218–222.10.1007/s11904-012-0119-7
   PubMed Web of Science ®Google Scholar
• Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17(13):1917–1923.10.1097/00002030-200309050-00010
   PubMed Web of Science ®Google Scholar
• Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22(3):395–402.10.1097/QAD.0b013e3282f423dd
   PubMed Web of Science ®Google Scholar
• Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon I, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab. 2012;97(2):554–562.10.1210/jc.2011-2197
   PubMed Web of Science ®Google Scholar
• Chiţu-Tișu CE, Barbu EC, Lazăr M, Ion DA, Bădărău IA. Low bone mineral density and associated risk factors in HIV-infected patients. Germs. 2016;6(2):39–48.
   Google Scholar
• Choe PG, Choi HJ, Kim NH, Park WB, Song KH, Bang JH, et al. High prevalence of low bone mass and associated factors in Korean HIV-positive male patients undergoing antiretroviral therapy. J Int AIDS Soc. 2014;17:187–193.
   Web of Science ®Google Scholar
• Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893–897.10.1016/j.bone.2005.11.001
   PubMed Web of Science ®Google Scholar